Clinical trials: Obese Subjects
Insulin Sensitivity
The Effect of TLR4 Inhibition in Obese and Type 2 Diabetic Subjects
To determine whether pharmacologic inhibition of Toll-like receptor 4 (TLR4) with eritoran for injection (E5564) will reduce inflammation and improve glucose metabolism in insulin resistant (obese and T2DM) subjects.
- Trial name
- Eritoran2 (NCT02267317)
- Testing
- Eritoran, D5W
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Obesity; Overweight
Effect of GLP-1 Analogue ROSE-010 on Appetite in Overweight and Obese Subjects
The primary objective of this study is to assess the efficacy of ROSE-010 on food intake in female subjects with overweight and obesity.
- Trial name
- NCT06621017
- Testing
- ROSE-010 99 mcg, ROSE-010 150 mcg
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Rose Pharma Inc
Weight Loss
Safety and Efficacy of IQP- AK-102 in Reducing Body Weight
The individual ingredients in IQP-AK-102 have been widely used. Backed by data from several studies demonstrating their efficacy, we are conducting this study to look into the efficacy and safety of this novel combination of…
- Trial name
- NCT01905956
- Testing
- IQP-AK-102
- Where
- Germany
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- InQpharm Group
Obesity
A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects
Following screening, eligible subjects will be enrolled into a 6-week Low Calorie Diet (LCD) lead-in period. Subjects who lose at least 2% of their body weight at the end of the 6-week LCD lead-in period will be randomized to 1…
- Trial name
- NCT01235741
- Testing
- Pramlintide+Metreleptin
- Where
- 18 sites in United States
- Volunteers
- 213 people
- Sponsor
- AstraZeneca
Overweight, Obesity
Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program
This study will look at the change in participant's body weight from the start to the end of the study. This is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy"…
- Trial name
- STEP 3 (NCT03611582)
- Testing
- Semaglutide
- Where
- 41 sites in United States
- Volunteers
- 611 people
- Sponsor
- Novo Nordisk A/S
Vitamin D Deficiency
Vitamin D Supplementation Requirement in Obese Subjects
Vitamin D deficiency is common in obese patients. Most of vitamin D supplementation studies were done with non-obese subjects. This study looks at vitamin D supplementation requirements in obese patients as compared to non-obese…
- Trial name
- NCT00996866
- Testing
- Vitamin D3
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Winthrop University Hospital
Blood Pressure
A Study of VI-0521 on Ambulatory Blood Pressure (ABPM) in Overweight or Obese Subjects
The study is being conducted to evaluate the effect of VI-0521 (Qsymia®) on blood pressure as measured by 24-hour ambulatory blood pressure monitoring, compared to both placebo and an active control (phentermine 30 mg).
- Trial name
- NCT05215418
- Testing
- VI-0521, Phentermine
- Where
- 28 sites in United States
- Volunteers
- 565 people
- Sponsor
- VIVUS LLC
Metabolism and Nutrition Disorder, Obesity
The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes
This trial is conducted in Europe. The purpose of the 20-week trial is to investigate the efficacy of liraglutide to induce body weight loss and the purpose of the extension is to evaluate the long term safety and tolerability of…
- Trial name
- NCT00422058
- Testing
- liraglutide, orlistat
- Where
- 19 sites in Belgium, Czechia and 6 more
- Volunteers
- 564 people
- Sponsor
- Novo Nordisk A/S
Obesity
Pharmacokinetics of Oseltamivir Carboxylate In Morbidly Obese Subjects
One in three Americans are obese. Obese subjects may or may not need higher doses of the anti-flu drug known as Tamiflu (oseltamivir).
- Trial name
- NCT01179919
- Testing
- Oseltamivir
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Manjunath Prakash Pai
Type 2 Diabetes Mellitus
A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
A phase 2 study in two parts (A \& B) designed to evaluate the effect of MEDI0382 on Hepatic Glycogen Metabolism in subjects with Type 2 Diabetes Mellitus (T2DM).
- Trial name
- NCT03555994
- Testing
- MEDI0382, Liraglutide
- Where
- 3 sites in Netherlands, Sweden and 1 more
- Volunteers
- 51 people
- Sponsor
- MedImmune LLC
Obesity
A Study of BioEnterics® Intragastric Balloon (BIB®) System to Assist in the Weight Management of Obese Subjects
Safety and effectiveness of the BIB® System in conjunction with a behavior modification program compared to the behavior modification program alone for weight loss in obese subjects.
- Trial name
- NCT00730327
- Testing
- BioEnterics® Intragastric Balloon, Behavioral modification
- Where
- United States
- Volunteers
- 448 people
- Sponsor
- Apollo Endosurgery, Inc.
Morbid Obesity, Bariatric Surgery Candidate
EPO2-PV: Evaluation of Pre-Oxygenation Conditions in Morbidly Obese Volunteer: Effect of Position and Ventilation Mode
The risk of complications associated with airway management in obese patients is significant. The results of pre-oxygenation allow a prolonged non-hypoxic apnea time for the clinician.
- Trial name
- EPO2-PV (NCT02121808)
- Testing
- NIPPV, Tidal volume
- Where
- Canada
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Laval University
Type 2 Diabetes
The Effect of LINAGLIPTIN on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes Subjects
This is a single center, prospective randomized double blind, parallel and placebo controlled study to evaluate oxidative stress and inflammation before and after treatment with linagliptin for 12 weeks.
- Trial name
- 1971 (NCT02372630)
- Testing
- Linagliptin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University at Buffalo
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles
Anxiety about needles is a concern commonly expressed by diabetics when beginning insulin therapy. A shorter, thinner pen needle that delivers insulin with the safety and efficacy profile of longer pen needles may appeal to many…
- Trial name
- NCT01231984
- Testing
- 4 mm x 32G Pen Needle, 8mm x 31G Pen Needle, 12.7mm x 29G Pen Needle
- Where
- 10 sites in United States
- Volunteers
- 293 people
- Sponsor
- Becton, Dickinson and Company
Type 2 Diabetes Mellitus
A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
A Phase 2 study with two cohorts of differing doses designed to evaluate the efficacy, safety and pharmacokinetics (PK) of MEDI0382 in patients with Type 2 Diabetes Mellitus (T2DM).
- Trial name
- NCT03244800
- Testing
- MEDI0382
- Where
- 5 sites in Germany
- Volunteers
- 65 people
- Sponsor
- MedImmune LLC
Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH)
A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH.
A Phase 2 study with 4 treatment groups of two differing doses and matched placebos designed to evaluate the safety (including hepatic safety), tolerability and pharmacodynamic effects of two dose levels of MEDI0382 in obese…
- Trial name
- NCT04019561
- Testing
- MEDI0382 high dose, MEDI0382 low dose
- Where
- 27 sites in United States, Puerto Rico
- Volunteers
- 74 people
- Sponsor
- MedImmune LLC
Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2
Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes
This study will look at how participants' daily life is affected by their heart failure. The study will also look at the change in participants' body weight.
- Trial name
- STEP HFpEF DM (NCT04916470)
- Testing
- Semaglutide
- Where
- 180 sites in United States, Argentina and 14 more
- Volunteers
- 617 people
- Sponsor
- Novo Nordisk A/S
GERD, Gastroesophageal Reflux Disease
LINX Reflux Management System in Subjects With GERD Who Have Previously Undergone a Laparoscopic Sleeve Gastrectomy
The purpose of this study is to evaluate the LINX device in patients who have previously undergone laparoscopic sleeve gastrectomy (LSG) for obesity and have chronic gastroesophageal reflux disease (GERD).
- Trial name
- RELIEF (NCT02429830)
- Testing
- LINX device
- Where
- 12 sites in United States
- Volunteers
- 30 people
- Sponsor
- Torax Medical Incorporated
Obesity
Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity
This study will look at how the participants daily life is affected by their heart failure. The study will also look at the change in participants body weight from the start to the end of the study.
- Trial name
- STEP-HFpEF (NCT04788511)
- Testing
- Semaglutide
- Where
- 146 sites in United States, Argentina and 11 more
- Volunteers
- 529 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
A Multiple-ascending-dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes Mellitus
A Phase 1/2, multiple dose study with 6 cohorts of ascending doses designed to evaluate the efficacy, safety and pharmacokinetics (PK) of MEDI0382 in participants with Type 2 Diabetes Mellitus (T2DM).
- Trial name
- NCT02548585
- Testing
- MEDI0382
- Where
- 11 sites in Germany
- Volunteers
- 113 people
- Sponsor
- MedImmune LLC